628692-18-2

Basic information

• Product Name: 2-PYRAZOL-1-YL-PHENYL-BORONIC ACID
• Synonyms: [2-(1H-PYRAZOL-1-YL)PHENYL]BORONIC ACID;2-PYRAZOL-1-YL-PHENYL-BORONIC ACID;2-PYRAZOL-1-YL-PHENYL-BORONIC ACID（WS205118）
• CAS NO: 628692-18-2
• Molecular Formula: C9H9BN2O2
• Molecular Weight: 187.99
• Mol File: 628692-18-2.mol

Chemical Properties

• Boiling Point: 394.8±44.0 °C(Predicted)
• Appearance: /
• Density: 1.20±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 8.26±0.58(Predicted)
• CAS DataBase Reference: 2-PYRAZOL-1-YL-PHENYL-BORONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-PYRAZOL-1-YL-PHENYL-BORONIC ACID(628692-18-2)
• EPA Substance Registry System: 2-PYRAZOL-1-YL-PHENYL-BORONIC ACID(628692-18-2)

Safety Data

• Hazardous Substances Data: 628692-18-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Pyrazol-1-yl-phenyl-boronic acid is used as a key intermediate in the synthesis of 1-Hydroxynaphthyridin-2(1H)-one derivatives, which are known for their anti-HIV properties. The incorporation of this boronic acid into the molecular structure of these derivatives contributes to their ability to inhibit the replication of the HIV virus, making them valuable agents in the development of antiretroviral therapies.
In the preparation of 1-Hydroxynaphthyridin-2(1H)-one derivatives, 2-Pyrazol-1-yl-phenyl-boronic acid plays a crucial role in the formation of the desired molecular framework, which is essential for the biological activity of these compounds. Its presence in the synthesis process allows for the creation of a diverse range of 1-Hydroxynaphthyridin-2(1H)-one derivatives with varying degrees of potency and selectivity against HIV, offering a broad spectrum of potential treatments for HIV-infected individuals.
Furthermore, the use of 2-Pyrazol-1-yl-phenyl-boronic acid in the synthesis of these anti-HIV agents highlights its potential as a versatile building block in the development of novel pharmaceutical compounds. Its unique structure and reactivity make it a valuable asset in the design and synthesis of new drugs targeting a wide range of diseases and conditions, beyond just HIV infection.